Myeloma cell therapies, now in pharma hands, move into spotlight
10 Takeover Targets to Watch This Fall
Κάντε like στη σελίδα μας στο facebook για να μαθαίνετε πρώτοι όλα τα νέα!! With the first gene therapy for blindness in the market, the door has been … Continue Reading Can Gene Therapy Become The Cure For Blindness?
The top 10 drug launches of 2019
Clinical Catch-up for June 10-14
Κάντε like στη σελίδα μας στο facebook για να μαθαίνετε πρώτοι όλα τα νέα!! Celgene and bluebird bio published interim data from CRB-401, their Phase I trial of bb2121, their CAR-T therapy in … Continue Reading Celgene and bluebird bio Rushing to Stay Ahead of the CAR-T Pack
Gene therapy: how much will it cost patients?
Janssen and MeiraGTx Sign $440 Million Deal to Develop Gene Therapies for Eye Diseases
The Celgene Legacy: Innovative Science and Price Gouging
The 20 Hottest Pipeline Drugs to Watch in 2019
It’s no secret there’s money in the pharmaceutical industry. While chief executive officers and c-suite leaders are often noted for receiving large paychecks, some companies also offer lucrative compensation to employees. This … Continue Reading Pharma and Biotech Companies Provide Top Salaries: Survey
Regeneron Pharmaceuticals and bluebird bio are teaming up. The companies will combine their expertise in the battle against cancer by leveraging Regeneron’s VelociSuite platform with bluebird’s cell therapy technologies to develop new cell … Continue Reading Regeneron and bluebird bio Team Up to Develop Cell Therapies for Cancer
In an era of unprecedented drug approvals for rare diseases, two late-stage drugs are upping the ante with their promise to cure disease rather than treat symptoms. First to market … Continue Reading Orphan drugs leveraging new tech promise to cure disease
CAR-T companies are on the rise, supported by growing investment flowing into CAR-T research, landmark approvals of CAR-T cell therapies by the U.S. FDA (Kymriah and Yescarta), and major acquisitions within … Continue Reading CAR-T Companies: The Meteoric Rise Of Cellular Immunotherapies
Genomic medicine is the future of healthcare. Spawned by the Human Genome Project (“HGP”), this precise and personal approach to medicine is an emerging discipline with enormous disruptive … Continue Reading Genomic Medicine: Catch The Gene Therapy Wave
Cambridge, Mass.-based bluebird bio’s LentiGlobin gene therapy is increasing hemoglobin levels in anemia patients battling sickle cell disease and beta thalassemia, which reduces the need for blood transfusions … Continue Reading Anemia Patients Benefit from bluebird’s LentiGlobin Gene Therapy, Trial Data Shows